- Home
- ARWR vs JANX Comparison
ARWR vs JANX Comparison
Compare ARWR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- JANX
- Stock Information
- Founded
- ARWR 2003
- JANX 2017
- Country
- ARWR United States
- JANX United States
- Employees
- ARWR N/A
- JANX N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- ARWR Health Care
- JANX Health Care
- Exchange
- ARWR Nasdaq
- JANX Nasdaq
- Market Cap
- ARWR 1.8B
- JANX 1.6B
- IPO Year
- ARWR 1993
- JANX 2021
- Fundamental
- Price
- ARWR $13.03
- JANX $25.56
- Analyst Decision
- ARWR Buy
- JANX Strong Buy
- Analyst Count
- ARWR 11
- JANX 7
- Target Price
- ARWR $41.44
- JANX $94.29
- AVG Volume (30 Days)
- ARWR 1.6M
- JANX 929.3K
- Earning Date
- ARWR 05-12-2025
- JANX 05-08-2025
- Dividend Yield
- ARWR N/A
- JANX N/A
- EPS Growth
- ARWR N/A
- JANX N/A
- EPS
- ARWR N/A
- JANX N/A
- Revenue
- ARWR $2,500,000.00
- JANX $9,336,000.00
- Revenue This Year
- ARWR $4,380.43
- JANX N/A
- Revenue Next Year
- ARWR $64.24
- JANX $250.58
- P/E Ratio
- ARWR N/A
- JANX N/A
- Revenue Growth
- ARWR N/A
- JANX 28.12
- 52 Week Low
- ARWR $9.57
- JANX $22.52
- 52 Week High
- ARWR $30.41
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- ARWR 47.38
- JANX 37.10
- Support Level
- ARWR $12.44
- JANX $24.13
- Resistance Level
- ARWR $14.97
- JANX $33.97
- Average True Range (ATR)
- ARWR 0.74
- JANX 2.01
- MACD
- ARWR 0.11
- JANX -0.61
- Stochastic Oscillator
- ARWR 37.01
- JANX 14.53
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.